Arthneeti
Latest: Jubilant Ingrev. Q2 FY27 (Jul–Sep 2026) results →This page is Q1 FY27 (Apr–Jun 2026).All Q1 FY27 results →
JI

Jubilant Ingrev.

Q1 FY27Chemicals & Petrochemicals

Jubilant Ingrevia Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Price₹706
Market cap₹11.4K Cr
P/E36.0
Updated25 Aug 2026
Read4 min read

What the Q1 FY27 call signalled

2 of 4 strong

RevenueModerate growth
MarginMargins steady
CapexCapex planned
Order bookOrder book rising

The short version

The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls. Jubilant Ingrevia has shown steady growth with EBITDA increasing from INR100 crore per quarter three years ago to INR209 crore recently, reflecting confident guidance on overall business performance.

From Jubilant Ingrev.'s Q1 FY27 earnings-call transcript · updated 25 Aug 2026.

Revenue & Sales Performance

Moderate growth
  • The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls.
  • Sequential improvement in revenue and EBITDA is anticipated in the coming quarters.
  • Fine Chemicals, CDMO, and Nutrition businesses are showing sequential volume growth and portfolio expansion.
  • New Niacinamide plant is rapidly ramping up capacity, currently at ~50% volumes, aiming for 70%+ by year-end.
  • CDMO business pipeline continues to expand, with over 25 confirmed molecules and a funnel of 100+ molecules with INR3,500+ crore peak revenue potential.
  • Volume growth supported by increased volumes in CDMO, Fine Chemicals, and Nutrition segments.

2 more points from Jubilant Ingrev.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jubilant Ingrev. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Jubilant Ingrevia is commissioning a new multipurpose plant by the end of the current calendar year, which is expected to strengthen their CDMO and Fine Chemicals growth roadmap (Page 4).
  • The company is actively evaluating new growth opportunities across high potential segments such as electronics, semiconductors, cosmetics, and nutrition (Page 7).
  • They are building a dedicated R&D and clean room facility at their Greater Noida site targeting the semiconductor and electronics segments (Page 4).

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jubilant Ingrev. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

Order book rising
  • The current confirmed molecules in the CDMO funnel stand at 25, up from 20 in the previous quarter.
  • The peak revenue potential from confirmed molecules was previously estimated at around INR1,500 crore, but this has not been updated due to the addition of early-stage molecules whose peak potential is uncertain.
  • There are more than 100 molecules in the broader pipeline, but this is dynamic with molecules moving in and out of confirmed and advanced stages.
  • The large CDMO contract has a revenue potential of $300 million over 5 years.
  • Revenue contribution from confirmed molecules is expected to be at least 25% of the Specialty and Nutrition portfolio.

2 more points from Jubilant Ingrev.'s call on order book

Create a free account to keep reading this call

Jubilant Ingrev. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹1.4K Cr, net profit ₹111 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Jubilant Ingrev.'s management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • Alufluoride (Q1 FY27)

    Revenue from operations for Q1 FY27 was ₹26.6 crore, down 39% YoY (Page 6, 7, 8). Key investor presentation takeaways from Alufluoride Ltd's Q1 FY27 investor pr

  • POCL Enterprises (Q1 FY27)

    466.03 crores (Page 12, 17, 11) . Key investor presentation takeaways from POCL Enterprises Ltd's Q1 FY27 investor presentation — and how it ranks against secto

  • Devson Catalyst (Q1 FY27)

    FY 2023-24: ₹5,577.59 Lakhs . Key investor presentation takeaways from Devson Catalyst Ltd's Q1 FY27 investor presentation — and how it ranks against sector pee

  • Ambani Orgochem (Q1 FY27)

    Financial highlights show Total Income in ₹ Lakhs: . Key investor presentation takeaways from Ambani Orgochem's Q1 FY27 investor presentation — and how it ranks

Compare:vs Solar Industriesvs Pidilite Inds.vs SRF

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jubilant Ingrev. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jubilant Ingrev. Q1 FY27 results?

The company expects sustained growth momentum driven by Specialty Chemicals and Nutrition segments, alongside a recovery in acetyls. Jubilant Ingrevia has shown steady growth with EBITDA increasing from INR100 crore per quarter three years ago to INR209 crore recently, reflecting confident guidance on overall business performance.

What is Jubilant Ingrev. share price analysis?

Jubilant Ingrev. currently shows a below-average growth signal. The stock trades at a P/E of 36.0 with a market cap of ₹11,442 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jubilant Ingrev. planning capital expenditure?

Jubilant Ingrevia is commissioning a new multipurpose plant by the end of the current calendar year, which is expected to strengthen their CDMO and Fine Chemicals growth roadmap (Page 4).

Keep Jubilant Ingrev. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.